{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T14:44:57Z","timestamp":1766760297961,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ijantimicag.2017.01.034","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T05:31:49Z","timestamp":1493184709000},"page":"93-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Outpatient treatment of osteomyelitis with telavancin"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5161-4836","authenticated-orcid":false,"given":"Claudia P.","family":"Schroeder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucinda J.","family":"Van Anglen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin H.","family":"Dretler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Prokesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quyen","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Krinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0010","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1086\/420939","article-title":"Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines","volume":"38","author":"Tice","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0015","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jac\/dks003","article-title":"Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement","volume":"67","author":"Chapman","year":"2012","journal-title":"J Antimicrob Chemother"},{"year":"2016","series-title":"Handbook of outpatient parenteral antimicrobial therapy for infectious diseases","key":"10.1016\/j.ijantimicag.2017.01.034_bib0020"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9343(03)00231-6","article-title":"Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy","volume":"114","author":"Tice","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/jac\/dkq445","article-title":"Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service","volume":"66","author":"Mackintosh","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/phar.1577","article-title":"Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus","volume":"35","author":"Gomes","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2015.05.008","article-title":"Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence","volume":"46","author":"Stefani","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0050","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijantimicag.2014.12.006","article-title":"The clinical positioning of telavancin in Europe","volume":"45","author":"Masterton","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2017.01.034_bib0065","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance","volume":"61","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jac\/dkn490","article-title":"Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model","volume":"63","author":"Yin","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0075","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1345\/aph.1Q331","article-title":"Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem","volume":"46","author":"Brinkman","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0080","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/jac\/dkr329","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"66","author":"Twilla","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0085","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jac\/dkr518","article-title":"Acute renal insufficiency during telavancin therapy in clinical practice","volume":"67","author":"Marcos","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.curtheres.2015.10.002","article-title":"Chemical stability of telavancin in elastomeric pumps","volume":"77","author":"Sand","year":"2015","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.ijantimicag.2017.01.034_bib0095","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"Van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T06:21:12Z","timestamp":1535869272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0924857917301346"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.034","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outpatient treatment of osteomyelitis with telavancin","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}